BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
BD Marks Milestone with First Phasix Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial
BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry
BD Expands BD MAX System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec
BD and ChemoGLO Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
